← Browse by Condition
Medical Condition
high grade b cell lymphoma
Total Trials
8
Recruiting Now
8
Trial Phases
Phase 1, Phase 1, Phase 2
Lymphoma trials span diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, Hodgkin lymphoma, mantle cell lymphoma, and T-cell lymphomas — each with distinct biology and treatment response. CAR-T cell therapy has established a new standard in relapsed/refractory DLBCL, and trials now aim to move this approach earlier in the treatment sequence.
Active trials evaluate bispecific antibodies (mosunetuzumab, epcoritamab, glofitamab), next-generation CAR-T cell products (CD19/CD22 dual targets, BCMA-targeting), BTK inhibitors in B-cell lymphomas, and total metabolic volume on PET as a predictive biomarker for treatment adaptation.
Frequently Asked Questions — high grade b cell lymphoma Clinical Trials
How many clinical trials are currently recruiting for high grade b cell lymphoma?
ClinicalMetric currently tracks 8 actively recruiting clinical trials for high grade b cell lymphoma, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 8. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for high grade b cell lymphoma?
high grade b cell lymphoma research spans Phase 1 (5 trials), Phase 2 (2 trials). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a high grade b cell lymphoma clinical trial?
Eligibility criteria for high grade b cell lymphoma trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 1 5
Phase 2 2
Top Sponsors
1 trial
1 trial
1 trial
1 trial
1 trial
Recruiting Clinical Trials
NCT06588205
Recruiting
Exploring the Clinical Impact of MYC Aberrations and Their Relationship With Microenvironment in Diffuse Large B Cell Lymphoma and High-Grade B Cell Lymphoma
Enrollment
200 pts
Location
Italy
Sponsor
Fondazione Italiana Linfomi - ...
NCT05660395 Phase 1
Recruiting
A Study to Evaluate the Pharmacokinetics and Safety of Loncastuximab Tesirine in Participants With Relapsed or Refractory Diffuse Large B-cell Lymphoma or High-grade B-cell Lymphoma With Hepatic Impairment (LOTIS-10)
Enrollment
56 pts
Location
United States, Brazi...
Sponsor
ADC Therapeutics S.A.
NCT04300998
Recruiting
Study of CAR-T Therapy in Older Patients
Enrollment
154 pts
Location
United States
Sponsor
Memorial Sloan Kettering Cance...
NCT05256641 Phase 1, Phase 2
Recruiting
Acalabrutinib Maintenance for the Treatment of Patients With Large B-cell Lymphoma
Enrollment
24 pts
Location
United States
Sponsor
Jonsson Comprehensive Cancer C...
NCT04594642 Phase 1
Recruiting
A Study of AZD0486 in Subjects With B-Cell Non-Hodgkin Lymphoma
Enrollment
227 pts
Location
United States, Austr...
Sponsor
AstraZeneca
NCT05653271 Phase 1
Recruiting
ACE1831 in Adult Subjects With Relapsed/ Refractory CD20-expressing B-cell Malignancies
Enrollment
42 pts
Location
United States, Hong ...
Sponsor
Acepodia Biotech, Inc.
NCT05455697 Phase 1, Phase 2
Recruiting
Tafasitamab, Retifanlimab, and Rituximab in Combination With Standard Therapy for the Treatment of Diffuse Large B-cell Lymphoma
Enrollment
35 pts
Location
United States
Sponsor
University of Washington
NCT06693830
Recruiting
ctDNA-guided Therapy Optimization in Newly Diagnosed DLBCL
Enrollment
40 pts
Location
United States
Sponsor
Hua-Jay J Cherng, MD
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: April 2026 · Data Methodology